Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

Quick Access

Favorites
Most Used

All Specialties

OpiCalc Logo
Clinical CalculatorsDrugsGuidelines
SpecsDrugsGuides
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Registry Hub
Peer-Reviewed Evidence
HomeDrug RegistryCompareABSTRAL vs AMOXICILLIN PEDIATRIC
Comparative Pharmacology

ABSTRAL vs AMOXICILLIN PEDIATRIC Comparison

Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.

Clinical EssentialsPharmacokineticsSpecial PopulationsSafety & MonitoringPregnancy & LactationClinical Insights
Differential Analysis

ABSTRAL vs AMOXICILLIN PEDIATRIC

Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.

View ABSTRAL Monograph View AMOXICILLIN PEDIATRIC Monograph
ABSTRAL
Opioid Analgesic
Category C
AMOXICILLIN PEDIATRIC
Penicillin Antibiotic
Category A/B
TL;DR — Key Differences
  • Drug class: ABSTRAL is a Opioid Analgesic; AMOXICILLIN PEDIATRIC is a Penicillin Antibiotic.
  • Half-life: ABSTRAL has a half-life of Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment; AMOXICILLIN PEDIATRIC has Terminal elimination half-life: 1-1.5 hours in children with normal renal function; prolonged to 7-21 hours in anuria..
  • No direct drug-drug interaction has been documented between ABSTRAL and AMOXICILLIN PEDIATRIC.
  • Pregnancy: ABSTRAL is rated Category C; AMOXICILLIN PEDIATRIC is rated Category A/B.

Last clinically reviewed: July 2026 · OpiCalc Medical Review Team

Clinical Essentials

ABSTRAL
AMOXICILLIN PEDIATRIC
Mechanism of Action
ABSTRAL

Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.

AMOXICILLIN PEDIATRIC

Amoxicillin is a semisynthetic penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). It blocks the transpeptidation step in peptidoglycan cross-linking, leading to cell lysis and death.

Indications
ABSTRAL

Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.

AMOXICILLIN PEDIATRIC

Treatment of infections caused by susceptible strains of microorganisms in conditions such as otitis media, sinusitis, pharyngitis, tonsillitis, pneumonia, bronchitis, urinary tract infections, skin and skin structure infections, and gonorrhea,Prophylaxis of infective endocarditis in patients undergoing dental or upper respiratory tract procedures (off-label but per ADA/AHA guidelines),Eradication of Helicobacter pylori (as part of combination therapy)

Standard Dosing
ABSTRAL

For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.

AMOXICILLIN PEDIATRIC

250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours for adults.

Direct Interaction
ABSTRAL
No Direct Interaction
AMOXICILLIN PEDIATRIC
No Direct Interaction

Pharmacokinetics

ABSTRAL
AMOXICILLIN PEDIATRIC
Half-Life
ABSTRAL

Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment

AMOXICILLIN PEDIATRIC

Terminal elimination half-life: 1-1.5 hours in children with normal renal function; prolonged to 7-21 hours in anuria.

Metabolism
ABSTRAL

Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.

AMOXICILLIN PEDIATRIC

Amoxicillin is primarily metabolized by hydrolysis to penicilloic acid, which is then excreted renally. It does not undergo extensive hepatic metabolism; renal clearance involves tubular secretion and glomerular filtration.

Excretion
ABSTRAL

Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal

AMOXICILLIN PEDIATRIC

Renal: 60-80% unchanged via glomerular filtration and tubular secretion; biliary: minor (<10%); fecal: <5%.

Protein Binding
ABSTRAL

80-85% bound primarily to albumin and alpha-1-acid glycoprotein

AMOXICILLIN PEDIATRIC

17-20% bound to serum proteins, primarily albumin.

VD (L/kg)
ABSTRAL

4-6 L/kg; large Vd indicates extensive tissue distribution

AMOXICILLIN PEDIATRIC

0.3-0.5 L/kg; reflects distribution into extracellular fluid and well-perfused tissues; crosses placenta and distributes into pleural, synovial, and peritoneal fluids.

Bioavailability
ABSTRAL

Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism

AMOXICILLIN PEDIATRIC

Oral: 75-90% (absorption is rapid but incomplete; food does not significantly affect absorption).

Special Populations

ABSTRAL
AMOXICILLIN PEDIATRIC
Renal Adjustments
ABSTRAL

No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.

AMOXICILLIN PEDIATRIC

Cr Cl 10-30 m L/min: administer every 12 hours. Cr Cl <10 m L/min: administer every 24 hours. Hemodialysis: administer dose after dialysis.

Hepatic Adjustments
ABSTRAL

For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.

AMOXICILLIN PEDIATRIC

No specific dose adjustment required for Child-Pugh A or B. Child-Pugh C: consider dose reduction based on clinical response.

Pediatric Dosing
ABSTRAL

Not approved for pediatric patients <18 years; safety and efficacy not established.

AMOXICILLIN PEDIATRIC

Neonates <4 weeks: 30 mg/kg/day divided every 12 hours. Infants and children >4 weeks: 20-50 mg/kg/day divided every 8 hours (mild-moderate infection) up to 80-100 mg/kg/day divided every 6-8 hours (severe infection).

Geriatric Dosing
ABSTRAL

Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.

AMOXICILLIN PEDIATRIC

No specific dose adjustment based solely on age; assess renal function and adjust accordingly due to age-related decline in GFR.

Safety & Monitoring

ABSTRAL
AMOXICILLIN PEDIATRIC
Black Box Warnings
ABSTRAL
FDA Black Box Warning

Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.

AMOXICILLIN PEDIATRIC
FDA Black Box Warning

No FDA black box warning.

Warnings/Precautions
ABSTRAL

Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.

AMOXICILLIN PEDIATRIC

Serious hypersensitivity reactions (anaphylaxis) may occur; discontinue therapy if allergic reaction occurs. Clostridium difficile-associated diarrhea (CDAD) can occur. Adjust dose in renal impairment. Use caution in patients with mononucleosis due to high incidence of morbilliform rash. Prolonged use may result in superinfection.

Contraindications
ABSTRAL

Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.

AMOXICILLIN PEDIATRIC

Hypersensitivity to amoxicillin or any penicillin derivative; history of anaphylactic reaction to beta-lactams.

Adverse Reactions
ABSTRAL
Data Pending
AMOXICILLIN PEDIATRIC
Data Pending
Food Interactions
ABSTRAL

Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.

AMOXICILLIN PEDIATRIC

Amoxicillin absorption is not significantly affected by food; may be taken with or without meals. However, to minimize gastrointestinal upset, administer with a small amount of food if needed. Avoid acidic beverages (e.g., fruit juices) within 1 hour of dosing as they may degrade the antibiotic.

Pregnancy & Lactation

ABSTRAL
AMOXICILLIN PEDIATRIC
Teratogenic Risk
ABSTRAL

FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.

AMOXICILLIN PEDIATRIC

Amoxicillin is classified as FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Human data from pregnant women indicate no increased risk of major birth defects across all trimesters. Caution in first trimester due to limited data, but generally considered safe.

Lactation Summary
ABSTRAL

Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.

AMOXICILLIN PEDIATRIC

Amoxicillin is excreted into breast milk in low concentrations (M/P ratio approximately 0.01-0.02). Considered compatible with breastfeeding; minimal risk of infant effects such as diarrhea or allergic sensitization. Monitor infant for potential gastrointestinal disturbances.

Pregnancy Dosing
ABSTRAL

Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.

AMOXICILLIN PEDIATRIC

Physiologic changes in pregnancy (increased renal blood flow, glomerular filtration rate, and volume of distribution) may lower serum concentrations. Standard dosing is generally adequate, but severe infections may require dose adjustment. No specific dose reduction recommended; monitor clinical response.

Maternal Safety Status
ABSTRAL
Category C
AMOXICILLIN PEDIATRIC
Category A/B

Clinical Insights

ABSTRAL
AMOXICILLIN PEDIATRIC
Clinical Pearls
ABSTRAL

ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.

AMOXICILLIN PEDIATRIC

Amoxicillin pediatric suspension is dosed based on body weight; typical dose is 20-40 mg/kg/day in divided doses every 8 hours. For high-dose therapy (e.g., resistant pneumococcus), 80-90 mg/kg/day in two divided doses. Shake suspension well before each dose. Use within 14 days after reconstitution; discard unused portion. Not for patients with severe renal impairment (Cr Cl <30 m L/min) without dose adjustment. Monitor for rash, diarrhea, and hypersensitivity reactions.

Patient Counseling
ABSTRAL

Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.

AMOXICILLIN PEDIATRIC

Take this medication exactly as prescribed; complete the full course even if your child feels better.,Shake the bottle well before each dose; measure the dose with the provided dosing device.,Refrigerate the suspension after mixing; do not freeze. Discard any unused portion after 14 days.,Do not give this medication if your child is allergic to penicillins or cephalosporins.,Common side effects include diarrhea, nausea, and rash. Contact your doctor if severe diarrhea or signs of allergic reaction occur.,This medication may reduce the effectiveness of oral contraceptives; use additional birth control if applicable.,Inform your doctor if your child has kidney disease, phenylketonuria (some suspensions contain phenylalanine), or is pregnant/breastfeeding.

Safety Verification

Known Interactions

ABSTRAL Risks

No interactions on record

AMOXICILLIN PEDIATRIC Risks3
Amoxicillin + Indinavir
moderate

"Amoxicillin may reduce the metabolism of Indinavir via inhibition of CYP3A4, leading to increased plasma concentrations of Indinavir. This can elevate the risk of Indinavir-related toxicities such as nephrolithiasis, hepatotoxicity, and gastrointestinal intolerance. Patients may experience exacerbated adverse effects without a corresponding increase in antiviral efficacy."

Amoxicillin + Nicardipine
moderate

"Amoxicillin may inhibit the CYP3A4-mediated metabolism of nicardipine, a calcium channel blocker, leading to increased plasma concentrations of nicardipine. This can potentiate vasodilation and negative chronotropic effects, resulting in an increased risk of hypotension, bradycardia, and peripheral edema. Patients, especially those with pre-existing cardiovascular conditions, should be monitored for enhanced antihypertensive effects and adverse reactions when these drugs are coadministered."

Amoxicillin + Bortezomib
moderate

"Amoxicillin may inhibit the metabolism of bortezomib through competitive inhibition of cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19, potentially leading to increased bortezomib exposure. This interaction could result in enhanced toxicity of bortezomib, including peripheral neuropathy, myelosuppression, and gastrointestinal adverse effects. Clinicians should monitor for signs of bortezomib toxicity when amoxicillin is coadministered, especially in patients with pre-existing hepatic impairment or other risk factors."

Compare Alternatives

Related Drug Comparisons

Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.

ABSTRAL vs ACEPHENNon-Opioid Analgesic
AMOXICILLIN PEDIATRIC vs ACEPHENNon-Opioid Analgesic
ABSTRAL vs ACTIQOpioid Analgesic
AMOXICILLIN PEDIATRIC vs ACTIQOpioid Analgesic
ABSTRAL vs ALFENTAOpioid Analgesic
AMOXICILLIN PEDIATRIC vs ALFENTAOpioid Analgesic
ABSTRAL vs ALFENTANILOpioid Analgesic
AMOXICILLIN PEDIATRIC vs ALFENTANILOpioid Analgesic
ABSTRAL vs ANEXSIAOpioid Analgesic Combination
Clinical Q&A

Frequently Asked Questions

Common clinical questions about ABSTRAL vs AMOXICILLIN PEDIATRIC, answered by our medical review team.

1. What is the main difference between ABSTRAL and AMOXICILLIN PEDIATRIC?

ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. AMOXICILLIN PEDIATRIC is a Penicillin Antibiotic that works by Amoxicillin is a semisynthetic penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). It blocks the transpeptidation step in peptidoglycan cross-linking, leading to cell lysis and death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.

2. Which is stronger: ABSTRAL or AMOXICILLIN PEDIATRIC?

Potency comparisons between ABSTRAL and AMOXICILLIN PEDIATRIC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.

3. What is the standard dosing for ABSTRAL vs AMOXICILLIN PEDIATRIC?

The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. The standard adult dose of AMOXICILLIN PEDIATRIC is: 250-500 mg orally every 8 hours or 500-875 mg orally every 12 hours for adults.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.

4. Can you take ABSTRAL and AMOXICILLIN PEDIATRIC together?

No direct drug-drug interaction has been formally documented between ABSTRAL and AMOXICILLIN PEDIATRIC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.

5. Are ABSTRAL and AMOXICILLIN PEDIATRIC safe during pregnancy?

The maternal-fetal safety profiles differ. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. AMOXICILLIN PEDIATRIC is classified as Category A/B. Amoxicillin is classified as FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Human data from pregnant women indicate no increased risk of major birth def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.